Deployment o the Multidisciplinary Prospective Cohort Imminent
Deployment o the Multidisciplinary Prospective Cohort Imminent
What it found
No result yet.
What was tested
Treatment tested
- Biobanking with genetic analysis
- SF-12 questionnaire
What it measured
Main measures
Change of SLEDAI for lupus
once a year for 10 years
Walking and mobilityChange of Medsger score
once a year for 10 years
Change of EDSS for multiple sclerosis
once a year for 10 years
Disability progressionFatigueChange of BASDAI for psoriatic arthristis
once a year for 10 years
FatiguePainChange of Longhurst criteria for hereditary angioedema
once a year for 10 years
Change of number of flares for atopic dermatitis
once a year for 10 years
Change of number of exacerbations for severe asthma
once a year for 10 years
Change of 12-Item Short-Form Health Survey (SF-12) - quality of life scale
once a year for 10 years
Quality of life (reported by participants)number of participant with severe infectious events
once a year for 10 years
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* Patient followed for their IMID in one of the departments of the Lille University Hospital participating in the study (dermatology, internal medicine, neurology, pneumology and rheumatology) * Social insured * Have the capacity to understand the study requirements, provide written informed consent, and comply with the study data collection procedures.
Exclusion criteria
* Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system. * Pregnant or breastfeeding woman * Persons deprived of liberty * Protected minors or adults * Persons who have refused or are incapable of giving informed consent * Persons in Emergency Situations
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions. Beyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as "targeted therapies". Despite progress in this field, much remains to be done in clinical, therapeutic and fundamental research to address the efficacy, resistance and side-effects of treatment. These similarities between IMIDs have led the FHU IMMINeNT to propose the creation of a prospective, multidisciplinary clinical-biological database (IMMINeNT cohort), associated to a biobank, of patients with IMIDs. The main objectives of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets and biomarkers, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with IMIDs as well as to the response and tolerance to treatment.
Papers
Loading reviews and guidelines…
History
Started
Jul 2020
Main results due
Jul 2031
Finished
Jul 2031